Skip to Main Content

Paper Details

Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With <i>EGFR</i>-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study.
JTO Clin Res Rep
11
2020
Author NameAffiliation
Collin M BlakelyUniversity of California San Francisco Helen Diller Family Comprehensive Cancer Center
  • 1 - 1

Datasets

Release 1.2